The Role of Immune Checkpoints in Lung Transplant (ILTRA)

Launched by FONDAZIONE IRCCS CA' GRANDA, OSPEDALE MAGGIORE POLICLINICO · Mar 6, 2024

Keywords

ClinConnect Summary

The ILTRA trial is a study aimed at understanding lung transplant rejection, specifically looking at the role of immune checkpoints in this process. Immune checkpoints are like switches that can turn the immune system on or off, and researchers want to see how they affect whether a transplanted lung is accepted or rejected by the body. To do this, they will analyze lung tissue from patients who have undergone a transplant and compare it to samples taken during routine check-ups.

To participate in this study, you need to be a lung transplant patient. However, individuals who have had severe immune reactions or a history of autoimmune disorders (where the immune system attacks the body’s own cells) will not be eligible. If you join the study, you will help researchers learn more about how the immune system interacts with transplanted lungs, which could lead to better treatments and outcomes for future patients. The trial is not yet recruiting participants but aims to gather valuable insights for improving lung transplant care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Lung transplant patients
• Exclusion Criteria:
• • Hyperimmunized patients
• • History of auto-immune disorders